Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV

Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 19.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 917,975 shares of the specialty pharmaceutical company’s stock after acquiring an additional 149,003 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 1.82% of KalVista Pharmaceuticals worth $11,181,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of KALV. The Manufacturers Life Insurance Company boosted its holdings in shares of KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after purchasing an additional 818 shares during the period. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. Rhumbline Advisers boosted its stake in KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its stake in KalVista Pharmaceuticals by 26.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after buying an additional 2,061 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after acquiring an additional 2,939 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $16.54 on Friday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock has a market cap of $836.10 million, a price-to-earnings ratio of -4.19 and a beta of -0.14. The firm has a 50-day moving average of $15.28 and a two-hundred day moving average of $13.82. KalVista Pharmaceuticals, Inc. has a 1 year low of $8.40 and a 1 year high of $19.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Brian Piekos sold 4,471 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer directly owned 10,529 shares in the company, valued at $141,615.05. The trade was a 29.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,294 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $16.51, for a total transaction of $120,423.94. Following the transaction, the chief executive officer owned 424,520 shares in the company, valued at approximately $7,008,825.20. The trade was a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 31,329 shares of company stock worth $437,371. 4.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on KALV shares. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC boosted their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Citizens Jmp reduced their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Finally, HC Wainwright boosted their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.17.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.